MULTIPLE PATH PARTICLE DOSIMETRY FOR PREDICTION OF MOUSE LUNG DEPOSITION OF NANOAEROSOL PARTICLES by Ali, Mohammed
University of Texas at Tyler
Scholar Works at UT Tyler
Technology Faculty Publications and Presentations Technology
8-2017
MULTIPLE PATH PARTICLE DOSIMETRY
FOR PREDICTION OF MOUSE LUNG
DEPOSITION OF NANOAEROSOL
PARTICLES
Mohammed Ali
The University of Texas at Tyler, mohammedali@uttyler.edu
Follow this and additional works at: https://scholarworks.uttyler.edu/tech_fac
Part of the Biomedical Engineering and Bioengineering Commons, Circulatory and Respiratory
Physiology Commons, and the Medical Toxicology Commons
This Article is brought to you for free and open access by the Technology at Scholar Works at UT Tyler. It has been accepted for inclusion in
Technology Faculty Publications and Presentations by an authorized administrator of Scholar Works at UT Tyler. For more information, please contact
tbianchi@uttyler.edu.
Recommended Citation
Ali, Mohammed, "MULTIPLE PATH PARTICLE DOSIMETRY FOR PREDICTION OF MOUSE LUNG DEPOSITION OF
NANOAEROSOL PARTICLES" (2017). Technology Faculty Publications and Presentations. Paper 3.
http://hdl.handle.net/10950/1896
http://www.iaeme.com/IJARET/index.asp 10 editor@iaeme.com 
International Journal of Advanced Research in Engineering and Technology (IJARET)  
Volume 8, Issue 4, July - August 2017, pp. 10–20, Article ID: IJARET_08_04_002 
Available online at http://www.iaeme.com/IJARET/issues.asp?JType=IJARET&VType=8&IType=4 
ISSN Print: 0976-6480 and ISSN Online: 0976-6499 
© IAEME Publication 
 
MULTIPLE PATH PARTICLE DOSIMETRY FOR 
PREDICTION OF MOUSE LUNG DEPOSITION 
OF NANOAEROSOL PARTICLES 
M. Ali 
Department of Technology, 
The University of Texas at Tyler, Longview, Texas 75605, USA 
B. W. Gutting, M. L. van Hoek 
School of Systems Biology 
George Mason University, Manassas, Virginia 20110, USA 
ABSTRACT 
Nanoaerosolized particle (dia.<200 nm) antibiotic inhalation therapy was tested 
to treat pneumonic tularemia in mice caused by Francisellanovicida infection. Very 
limited experimental techniques are available to properly estimate inhaled doses and 
distribution of the drug inside the mouse lungs. To overcome this problem, 
computational simulation of particle deposition based on the Multiple Path Particle 
Dosimetry (MPPD) model was employed to simulate in vivo experimental conditions 
which included nasal breathing with whole body exposure to the antibiotic in the form 
of nano-aerosolized medicine. The deposition results were compared with several in 
vivo experimental data reported in literature; and satisfactory agreements were found. 
Comparing with in vivo experimental data, regional deposition results are very close 
with ±10-15% variations. After testing application of the MPPD model, the total 
inhaled doses of levofloxacin encapsulated into nanoliposomes were estimated which 
take into account distribution of sizes of nanoaersol particles.  Thus, we have 
demonstrated that MPPD can be used to model the deposition of nanoaerosol 
particles in mice.  
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1. INTRODUCTION 
Present knowledge reveals that the nanoparticle (NP) (an object with at least one dimension 
less than 100 nm) and ultrafine particle (UFP) (100 nm <dia.< 1000 nm) are highly effective 
in deep lung and/or alveolar penetration [1-4]. The key factors that contribute to the 
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effectiveness of NPs and UFPs transport and deposition are still not clear; however, literature 
suggests that simultaneous actions of their mass, number and surface area concentrations are 
important factors [5,6]. 
Lung delivery of nebulized liposomal Amikacin has been demonstrated success in 
reducing Pseudomonas infection in the cystic fibrosis human lung [7]. However, although 
effective, these aerosols contain large particles in the 5-10 µm range, as they are generated by 
a vibrating mesh nebulizer system [8], and will have limited penetration to the deep lung. The 
hypothesis of Morozov and van Hoek is that nanoaerosols enable delivery of a clinically 
effective outcome with a lower dose due to alveolar penetration of the nano-sized aerosol 
particles [9].  Morozov[10] showed that biologically active substances can be aerosolized by 
using electro-spray nanoaerosol generator with count median aerodynamic diameter (CMAD) 
in the range of 20-200 nm. Therapeutic action of thus atomized drugs shows notable 
difference from action of the same drug introduced via different routes. For example, the 
clinically effective dose of nanoaerosolized indomethacin was found to be six orders of 
magnitude less than the oral dose required for the same effect [11].   
These concepts were further established by recent in vivo studies that showed efficiency of 
inhalation therapy by delivering nanoaerosol of the liposome encapsulated levofloxacin (LEL) 
in treatment of tularemia in mice caused by Francisellanovicida[12].  Francisella infection is 
known to be susceptible to levofloxacin [13], and liposomal ciprofloxacin was found to be an 
improved formulation over ciprofloxacin alone [14]. Thus, we generated nanoaerosols of 
liposome-encapsulated levofloxacin and used them for the therapeutic aerosol treatment of 
mice infected with pneumonic tularemia [12].  It required 94 times less than the oral required 
dose and approximately 8 times lower than the intraperitoneal dose when the LEL 
nanoaerosol was delivered to the diseased lung of BALB/c mice in the form of nanoaerosol 
(dia.<200 nm). This success opened an enthusiasm to understand how the LEL nanoaerosols 
get transported, disseminated and deposited inside the mouse lung.  
 Pulmonary drug delivery (PDD) is of significant interest due to many advantages of PDD 
such as (i) a large surface area of lungs (about 100 m2) accessible to rapid absorption provided 
by terminal bronchioles and alveoli, (ii) a thin (0.1–0.2 mm of alveolar epithelium) physical 
barrier for absorption, promoting rapid uptake into the bloodstream, (iii) the absence of 
extreme pH, (iv) no first-pass liver metabolism as compared to oral introduction, with 
minimum reduction of bioavailability, (v) rich blood supply, (vi) rapid systemic delivery from 
alveolar region to the blood, and (vii) minimal extracellular enzyme levels for metabolic 
breakdown compared with the gastrointestinal tract, (viii) bypass digestive complications, 
extracellular enzymes and interpatient metabolic differences that result from gastrointestinal 
absorption [15-17]. Targeted aerosol delivery to the lung tissue may improve therapeutic 
efficiency and minimize unwanted side effects [9]. 
Despite enormous progress in optimizing aerosol delivery to the lung, targeted aerosol 
delivery to specific lung regions other than the large airways or the lung periphery has not 
been adequately achieved to date [18]. Additionally, the in vivo data on respiratory deposition 
of nanoaerosols in various regions of the mice lungs are very limited. 
In order to better understand deposition patterns of nano-sized aerosols, and to resolve the 
issues of disparate findings from in vivo results it is necessary to understand the drug 
dosimetry. With this aim in mind, the present work employed mathematical expression based 
semi-empirical multiple path particle dosimetry (MPPD, version 3.0) computational tool to 
simulate inhaled nanoaerosol deposition. The study objectives were: 1) to predict inhaled LEL 
nanoaerosols deposition in various lung regions, 2) to correlate these computational results 
with in vivo experimental data, and 3) to estimate real doses obtained in treatment of mice 
with nanoaerosols of antibiotics. 
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1.1. Relevant Concepts and Theories  
Mouse models are often used in studies to understand disease development, progression, and 
treatment. Studies showed that mouse lung airway dimensions e.g., length, cross-section 
significantly differ between B6C3F1 and BALB/c strains [19,20]. Total lung deposition is 
species dependent i.e., interspecies differences in total lung deposition may occur [21]. A 
decrease in total lung deposition occurs with increasing particle size.  ‘Respirable’ size range 
varies animal to animal e.g., mouse strains [22]. 
Figure 1 depicts various regions and the asymmetric branching pattern that exist in the 
normal anatomy of a BALB/c mouse lung [23]. Literature defined extrathoracic (ET) or Head 
region (head, including nasal cavity, mouth, pharynx and larynx [24], tracheobronchial region 
(TB, including trachea, main and lobar bronchi, up to terminal bronchioles) [25], and 
pulmonary (P, including respiratory bronchioles, alveolar ducts and sacs) [26].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Asymmetric branching pattern of the BALB/c mice lung and various regions (extrathoracic 
(ET) or Head, tracheobronchial (TB), and pulmonary (P)) 
Distribution of inhaled nanoaerosols deposition in the lung airways is governed by five 
deposition mechanisms.  They are: 1) inertial impaction, 2) Brownian diffusion, 3) 
gravitational settling, 4) interception, and 5) electrostatic attraction [27-29].  The respiratory 
deposition fraction (DF) of inhaled aerosols is dependent on the measure of DF with respect 
to GSD. Additionally, a bias arises if the DF of a polydisperse aerosol is utilized as a measure 
of DF for monodisperse aerosol or vice versa [30]. Present understanding on deposition 
mechanisms specific to the particular lung regions or anatomical units are: impaction and 
diffusion in the ET region, impaction, diffusion and sedimentation in the TB region, and 
diffusion and sedimentation in the P region [31]. 
2. MATERIALS &METHODS 
Obtaining regional deposition for mouse lung through in vivo experiments is challenging. 
Computational simulation based on mathematical expressions of aerosol particles transport 
and deposition may provide important insight in this endeavor. The asymmetric multiple-path 
particle dosimetry (MPPD, version 3.0) model was adopted in this study. MPPD was 
originally developed by the Chemical Industry Institute for Toxicology (CIIT), Research 
Triangle Park, North Carolina, USA. CIIT was later acquired by the Applied Research 
TB 
Head 
Asymmetric 
branching 
P 
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Associates Inc., Albuquerque, New Mexico, USA and it allows the scientific community to 
use this software for academic or research purposes. Its performance was verified and 
reported in various studies [32-33]. It is widely used in the research and regulatory science 
communities.  
The MPPD program calculates multiple particles flow paths to multiple airways at any 
instant. It is a realistic model based on actual geometry of mouse lung airways by 
incorporating asymmetric branching pattern, and calculation is done for individual airway. 
Like other modeling studies the MPPD adopted 22 generation morphometry in its simulation. 
The model is applicable to both monodisperse and lognormally distributed polydisperse 
aerosols with a wide particle size range from 10 nm to 20 µm. It is able to calculate total 
deposition, as well as specific site of lung such as regional and lobar deposition. The 
deposition fraction can be plotted as a function of airway regions, generation number, various 
breathing patterns and particle concentrations. Deposition value is determined by using tree 
traversal procedure at proximal and distal ends. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (A) The aerodynamic size distribution of liposome encapsulated levofloxacin (LEL) nano-
aerosolized particles determined by scanning mobility particle sizer spectrometer. (B) Spectrum of 
non-encapsulated levofloxacin. 
The in vivo experimental study involved inhalation by free-breathing mice in a whole 
body exposure chamber of LEL nanoaerosols for 4 hours/day and 5 days consecutively [12]. 
These data were used as some of the input parameters of MPPD which employs mathematical 
expressions of lung deposition mechanisms in computer simulation to calculate the particle 
dosimetry. MPPD incorporated other LEL nanoaerosol properties specifically, CMAD of 80 
nm, geometric standard deviation (1.63), aerosol concentration (3,580 mg/m3) and 
physiological conditions of the mouse lung such as nasal breathing rate (144.6 l/min), 
functional residual capacity (FRC) 0.6 ml, tidal volume (0.20 ml) and inhalability correction 
was also included. 
Figure 2 shows the aerodynamic size distribution of the LEL nanoaerosols determined by 
a scanning mobility particle sizer spectrometer (TSI Inc., Shoreview, Minnesota, USA). 
(A) 
(B) 
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Deposition results were calculated as the regional (Head, TB, P) and thoracic (TB+P) 
fractions for the whole lung.   
Furthermore, to compare with available in vivo information in the literature reported by 
Koivisto et al [34], Alessandrini et al [23], Kuehl et al [35], and Raabe et al [36], our MPPD 
simulation parameters for various experimental scenarios were as close as possible to the 
scenarios used in these studies. 
3. RESULTS AND DISCUSSION  
The predictive power of MPPD was demonstrated in a comprehensive study on FVBN/J mice 
for silver oxide nanoparticles conducted by Asgharian et al [33]. They have found a 
reasonable agreement when comparing predicted deposition factions with four experimental 
studies undertaken by Raabe et al [36] on CF1 mice; Oldham et al [37] on BALB/c mice; 
Kuehl et al [35] on B6C3F1 mice, and Hsieh et al [38] on C57BL/6 mice. Lung and breathing 
parameters in each of these studies were used in MPPD model predictions. 
3.1. Fit with known data of Propst et al [12] 
Simulation output shows that the nanoaerosols with aerodynamic diameter 40 nm (Figure 3) 
are deposited more highly in the pulmonary or respiratory region compared to TB and Head 
regions, where larger particles tend to deposit better.  
 
Figure 3 Comparison of deposition fraction of liposome encapsulated nanoaerosol particles in 
tracheobronchial (TB), pulmonary (P) and thoracic (TB+P) regions of mice lung. 
The calculated deposition fraction of monodisperse aerosol in central respiratory airway is 
about 19% while 14% in the peripheral conducting airways. Our calculation also shows that 
about 37% LEL particles deposited in the lung’s Head, TB and P regions combined, and the 
remaining portion gets exhaled. In the pulmonary region, we calculated that about 6% 
particles get deposited. A cross-simulation study showed that the LEL deposits 2% more than 
non-encapsulated levofloxacin. This phenomenon can be due to the larger size upon liposome 
encapsulation as seen from comparison of spectra on Figures 2A and 2B. These larger 
particles might experience higher impaction force while flowing through head airways. 
Figure 4 shows the total predicted deposition fractions in the lung’s Head, TB and P 
regions. The deposited mass in the pulmonary region is about 70 ng of nanoaerosols upon 
simulating mass fraction versus lung generation numbers. It is our understanding that these 
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particles would probably deliver maximum therapeutic and systemic effects in the deep lung 
which contains alveolar sacs. 
 
Figure 4 Comparison of deposition fraction of liposome encapsulated nanoaerosol particles in head 
airway, tracheobronchial (TB), pulmonary (P) regions and total (Head + TB + P) lung of mice. 
When considering a range of aerosols from nano to submicron sizes (refer to Figure 3), 
the LEL nanoaerosols larger than 200 nm poorly deposit in the TB and P regions but greatly 
deposit in the Head region which can be explained by the predominance of inertial impaction 
and sedimentation mechanisms combined effects.  
It has been observed that the increase of submicron particle size increases Head deposition 
(refer to Figure 4).  Moreover, nanoparticles of 10-30 nm diameter range has low tendency to 
deposit in the Head and TB airways but high in the P region due to high diffusivity. The 50 
nm particle deposits equally in TB and P regions whereas particles with the size of 80 nm or 
higher poorly deposit in the TB and P regions. Inhaled particles clearance is assumed to occur 
primarily due to mucociliary movement inside TB regions [39]. It was noticed that 
irrespective of accounting for this property as simulation parameter, the depositions for 
various monodisperse aerosols were unaffected for Head, TB and P regions. The mass 
clearance in the TB region was about 10 µg/min. The model prediction of deposited mass for 
TB and P regions were 0.68 µg/min and 0.55 µg/min, respectively.  
3.2. Fit with known data of Koivisto et al[34] and Alessandrini et al [23] 
Koivisto et al [34] conducted an in vivo study with TiO2 nanoaerosols (size range 10 nm to 60 
nm) to determine deposition in the BALB/c/Sca mice lungs and found pulmonary deposition 
of 11% for a single exposure. We calculated also the pulmonary deposition taking into 
account size of TiO2 nanoaerosols, and the deposition was calculated to be about 10% upon 
incorporating mouse’s physiological characteristics as close as possible to Koivisto’s study 
[34]. The precise parameters were: study subject BALB/c mouse, single exposure of 4 
hours/day, polydisperse aerosol size range 10 nm to 60 nm with concentration of 3580 mg/m3, 
nasal breathing of 144.6 l/min, FRC 0.6 ml, and tidal volume of 0.20 ml. 
Alessandrini et al [23] undertook an in vivo experiment with BALB/c mice of 20 min 
exposure for 2 days, tidal volume of 0.229 ml, and minute ventilation 110 ml/min. The 
experimental aerosols contained iridium ultrafine particles with CMAD 35 nm, count 
concentration 9.8 ± 0.9 x 106 /cc, GSD 1.7, mass concentration 0.2 mg/m3. In that study, the 
total lung deposition was estimated as 42%, of which 38% were deposited in the conducting 
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airways and 62% in the alveolar region [23]. The MPPD simulation performed with these 
input parameters predicted a total deposition of 45% where the Head, TB and P regions 
accounted for 37%, 27% and 36%, respectively.  
3.3. Fit with known data of Kuehl et al [35] 
Kuehl and other co-workers conducted an in vivo study with C57BL/6 mice restrained and 
nose-only inhalation for 4 minutes to determine regional lung deposition of radiolabeled 
polydisperse aerosols of 0.5, 1.0, 3.0 and 5.0 µm MMAD [35]. They have reported that the 
deposition patterns of aerosols between 0.5 and 5.0 µm showed an increase in overall and 
peripheral deposition as the particle size decreased. To compare with these data the MPPD 
simulation input parameters were chosen as close as possible to the Kuehl et al [35]. The 
precise parameters were: study subject BALB/c mouse, exposures of 4 hrs/day for 5 days, 
monodisperse aerosols of MMAD 0.5, 1.0, 3.0 and 5.0 µm with concentration of 3580 mg/m3, 
nasal breathing of 144.6 l/min, FRC 0.6 ml, tidal volume of 0.20 ml and clearance not 
considered. 
Table 1 Comparison between MPPD predicted liposome encapsulated nanoaerosol particles 
deposition in mouse lungs’ various regions with in vivo results of Kuehl et al [35]. 
Particle dia.  
MMAD (µm) 
MPPD(%) Kuehl et al [35](%) 
Head TB P Oral/nasal TB P 
0.5 25.6 3.8 5.6 28.6 2.0 10.7 
1.0 38.1 3.1 3.8 58.0 8.2 2.2 
3.0 50.2 2.2 1.9 46.6 4.7 2.3 
5.0 43.5 1.3 1.2 61.7 4.5 0.2 
 
As seen from the results presented in Table 1, the MPPD simulated data are very much 
agreed for the Head regional deposition whereas for the TB region, MPPD depositions is 
about twice as high for 0.5 µm Nanoaerosols and 50% less for 1.0, 3.0 and 5.0 µm particles 
deposition reported in Kuehl et al [35] work. In contrary, the MPPD deposition for the P 
region is about 45% less for 0.5 µm, 80% more for 1.0 µm, 24% less for 3.0 µm, and 80% 
more for 5. µm particles compared to Khuel’s work. The possible reasons for this discrepancy 
between MPPD prediction and Kuehl et al [35] are: a) physiological differences in the mice 
strains BALB/c vs C57BL/6, b) exposure time 4 hrs per day for 5 days vs 4 min for 8 times 
on same day, and c) free mice in a cell filled with Nanoaerosols vs restrained and nose-only 
exposure to Nanoaerosols. 
3.4. Fit with known data of Raabe et al [36] 
Furthermore, the MPPD predicted LEL deposition in the mouse lung was compared with the 
data of in vivo study conducted by Raabe et al [36]. All the MPPD simulations’ input 
parameters were as close as possible to the Raabe’s data, and the simulation results are 
presented in Table 2. The precise parameters were: study subject BALB/c mouse, single 
exposure of 45 minutes, monodisperse aerosols of MMAD 190 nm and 767 nm with density 
2.46 g/cc and GSD 1.3, nasal breathing frequency 160/min, FRC 0.6 ml, and tidal volume of 
0.20 ml. In order to comply with MPPD’s acceptable unit for input particle size (aerodynamic 
diameter), we converted Raabe at al [36] reported aerodynamic resistance diameters 0.270 µm 
and 1.09 µm into aerodynamic diameters of 190 nm and 767 nm, respectively. 
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Table 2 Comparison between MPPD predicted liposome encapsulated nanoaerosol particles 
deposition in mouse lungs’ various regions with in vivo results of Raabe et al [36]. 
Particle dia.  
MMAD (nm) 
MPPD 
(%) 
Raabe et al [36] 
(%) 
TB P TB P 
190 7.82 12.37 14.48 45.4 
767 2.00 2.73 6.08 9.7 
 
Here the MPPD predicted TB and P deposition fractions are differed (TB, 50% and P, 
75%) (refer to Table 2) from the reported experimental data of Raabe et al [36].  The possible 
explanations of these variations can be:  a) MPPD is a semi-empirical mouse deposition 
model of BALB/c mice whereas Raabe’s experiment was on CFI mice, airway dimensional 
parameters differ between both species; b) MPPD adopted TB morphometry lung cast CT-
scan data to establish airway dimensional parameters [33]; c) MPPD predicts upper 
respiratory tract (includes TB) deposition due to impaction and lower respiratory tract 
(includes P) deposition due to impaction and gravitational settling [33], there could be 
unaccounted parameters such as Brownian diffusion, interception and electrostatic charge 
force which could be affecting the in vivo experiment, and d) Raabe’s experimental mice were 
restrained and only their noses were exposed to the aerosols whereas MPPD simulates free 
nasal breathing with whole body exposure to the experimental aerosol. 
4. CONCLUSIONS 
Although, there is no in vivo experimental data available on regional level deposition for LEL 
therapeutic nanoaerosols in mouse lungs, this work computationally (in silico) predicted the 
dosimetry information by employing the semi-empirical MPPD model. The MPPD model 
prediction compared favorably and closely with several in vivo experimental studies on other 
mouse strains. This work will open the scope for further studies to determine appropriate 
particle sizes of other inhalable antibiotics to produce the appropriate dose for target regions 
of the lung, and for the use of MPPD to model the deposition of nanoaerosols. 
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